Clinical implications of pharmacogenomics of statin treatment (Q36426816)

14 August 2017

1 reference

title

Clinical implications of pharmacogenomics of statin treatment (English)

1 reference

14 August 2017

1 reference

Mangravite LM

1

1 reference

PubMed ID

16550210

14 August 2017

Thorn CF

series ordinal

2

1 reference

PubMed ID

16550210

14 August 2017

Krauss RM

series ordinal

3

1 reference

14 August 2017

21 March 2006

1 reference

The Pharmacogenomics Journal

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

360-374

1 reference

14 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500384

14 August 2017

0 references

cites work

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Clinical Pharmacokinetics of Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Clinically relevant differences between the statins: implications for therapeutic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Response to “The efficacy of simvastatin is not influenced by CYP2D6 polymorphism” by Geisel et al

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Pleiotropic effects of statins: moving beyond cholesterol control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

CETP gene variation: relation to lipid parameters and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqI

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Rosuvastatin and the statin wars--the way to peace

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Current perspectives on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Underappreciated statin-induced myopathic weakness causes disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Transport mechanism for lovastatin acid in bovine kidney NBL-1 cells: kinetic evidences imply involvement of monocarboxylate transporter 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Simvastatin induces impairment in skeletal muscle while heart is protected.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The expression of lactate transporters (MCT1 and MCT4) in heart and muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Molecular clues into the pathogenesis of statin-mediated muscle toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Metabolism and function of coenzyme Q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

HMG-CoA reductase inhibitors and coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2allele of the platelet glycoprotein IIIa gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

Statins and risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

HMG CoA reductase inhibition reduces sarcolemmal Na+–K+ pump density

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500384

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500384

1 reference

14 August 2017

1 reference

PubMed ID

16550210